Travere Therapeutics (TVTX) EBIAT: 2011-2025
Historic EBIAT for Travere Therapeutics (TVTX) over the last 15 years, with Sep 2025 value amounting to $25.7 million.
- Travere Therapeutics' EBIAT rose 146.90% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.5 million, marking a year-over-year increase of 74.81%. This contributed to the annual value of -$321.5 million for FY2024, which is 14.56% up from last year.
- According to the latest figures from Q3 2025, Travere Therapeutics' EBIAT is $25.7 million, which was up 301.54% from -$12.8 million recorded in Q2 2025.
- Travere Therapeutics' EBIAT's 5-year high stood at $150.7 million during Q3 2023, with a 5-year trough of -$136.1 million in Q1 2024.
- In the last 3 years, Travere Therapeutics' EBIAT had a median value of -$60.3 million in 2024 and averaged -$44.3 million.
- Its EBIAT has fluctuated over the past 5 years, first crashed by 6,766.71% in 2021, then surged by 279.31% in 2023.
- Over the past 5 years, Travere Therapeutics' EBIAT (Quarterly) stood at -$88.8 million in 2021, then grew by 3.53% to -$85.6 million in 2022, then declined by 5.30% to -$90.2 million in 2023, then surged by 33.17% to -$60.3 million in 2024, then spiked by 146.90% to $25.7 million in 2025.
- Its last three reported values are $25.7 million in Q3 2025, -$12.8 million for Q2 2025, and -$41.2 million during Q1 2025.